Gene Editing Market Report 2026

The gene editing market size has grown rapidly in recent years. It will grow from $10.31 billion in 2025 to $12.28 billion in 2026 at a compound annual growth rate (CAGR) of 19%. The growth in the historic period can be attributed to discovery of crispr cas systems, academic gene editing research, development of zfn and talen technologies, availability of research funding, expansion of molecular biology tools.

The gene editing market size is expected to see rapid growth in the next few years. It will grow to $24.45 billion in 2030 at a compound annual growth rate (CAGR) of 18.8%. The growth in the forecast period can be attributed to clinical translation of gene editing therapies, regulatory approvals, innovation in next-generation editing tools, increased industry investment, expansion of precision medicine. Major trends in the forecast period include rapid adoption of crispr-based technologies, expansion of gene editing in cell line engineering, increased use in agricultural and animal genetics, growth in therapeutic gene editing research, rising demand for precision genome modification.

The increasing prevalence of genetic disorders is expected to drive the growth of the global gene editing market in the coming years. Genetic disorders are medical conditions caused by abnormalities or mutations in an individual’s DNA. These disorders can be inherited from parents or arise from spontaneous genetic mutations and can lead to a variety of health issues, either present at birth or developing later in life. Gene editing offers significant potential for treating severe genetic diseases such as sickle cell disease, Huntington’s disease, β-thalassemia, cystic fibrosis, Alzheimer’s, and Parkinson’s. For example, in April 2023, the National Library of Medicine (NLM), a US-based medical library, reported that an estimated 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia (AD) in 2023. This number could rise to 13.8 million by 2060 if medical breakthroughs to prevent, slow, or cure AD are not achieved. Therefore, the growing prevalence of genetic disorders is expected to propel the gene editing market.

Leading companies in the gene editing market are introducing innovative technologies, such as techniques using specialized cell-penetrating peptides, which offer advantages over existing methods and provide a competitive edge. This approach also has the potential to advance the development of next-generation cell therapies for cancer and other diseases. For instance, in April 2023, Penn Medicine, a US-based multi-hospital health system, discovered that protein fragments used by certain viruses to enter cells could also deliver CRISPR-Cas gene editing molecules into cells and their DNA-containing nuclei with very high efficiency and low cellular toxicity. This technique is expected to be particularly useful for modifying T cells and other patient-derived cells for cell therapies. One potential application is CAR T (chimeric antigen receptor T cell) therapy, which uses specially engineered immune cells from a patient to treat cancer. This new method promises significant improvements in speed, efficiency, and reduced cellular toxicity compared to current techniques.

In February 2024, Ginkgo Bioworks, a US-based biotechnology company, acquired Patch Biosciences for an undisclosed amount. This acquisition is part of Ginkgo’s strategy to strengthen its genetic medicine capabilities by integrating Patch’s AI-driven platform into its existing services, including gene therapy, cell therapy, and RNA therapeutics. The move aligns with Ginkgo’s broader strategy of expanding its portfolio through acquisitions of companies specializing in molecular medicine and AI-driven drug discovery. Patch Biosciences, a US-based biotechnology company, focuses on gene editing and the development of genetic medicines.

Major companies operating in the gene editing market are AstraZeneca plc, Thermo Fisher Scientific Inc., Merck KGaA, GE Healthcare Life Sciences, Agilent Technologies Inc., Lonza Group AG, PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., CRISPR Therapeutics, Promega Corporation, GenScript USA Inc., Integrated DNA Technologies Inc., Intellia Therapeutics Inc., DNA Script Inc., Dharmacon Inc., Precision Biosciences Inc., Editas Medicine Inc., OriGene Technologies Inc., Tecan Group Ltd., Sangamo Therapeutics Inc., Horizon Discovery Group plc, Addgene Inc., New England Biolabs Inc., Cellectis SA, Recombinetics Inc., Allele Biotechnology LLC, Transposagen Biopharmaceuticals Inc., Synthego Corporation, Beam Therapeutics Inc., Caribou Biosciences Inc., Inscripta Inc., Mammoth Biosciences Inc., ToolGen Inc., Mirus Bio LLC.

North America was the largest region in the gene editing market in 2025. Western Europe was the second largest region in the global gene editing market share. The regions covered in the gene editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene editing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gene editing market by increasing costs of imported reagents, laboratory instruments, and genome editing kits. Research institutes and biotech companies are most affected due to dependence on imported tools. These tariffs raise research costs by increasing consumable and instrumentation expenses for CRISPR and other editing workflows, affecting project scalability. However, they support domestic production of gene editing reagents, fostering regional self-sufficiency in advanced genomic research.

The gene editing market research report is one of a series of new reports that provides gene editing market statistics, including gene editing industry global market size, regional shares, competitors with a gene editing market share, detailed gene editing market segments, market trends and opportunities, and any further data you may need to thrive in the gene editing industry. This gene editing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene editing is a technology that enables the modification of genetic material at specific locations within a genome. It encompasses cell line engineering, animal genetic engineering, and plant genetic engineering.

The main types of gene editing technologies are CRISPR, TALEN, and ZFN. CRISPR is an advanced technology that allows geneticists and medical researchers to edit parts of the genome by removing, inserting, or altering DNA sequences. Its applications include biotechnology, pharmaceuticals, and contract research organizations, and it is used in animal genetic engineering, plant genetic engineering, and cell line engineering.

The gene editing market includes revenue earned by zinc-finger nucleases (ZFNs) and homing endonucleases or meganucleases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.